Revium Rx. Launches Dual Offering: IPO at $3.20, Resale at $1.00

TL;DR

**Revium Rx.'s dual offering is a red flag; the $1.00 resale price will crush the $3.20 IPO, making this a hard pass for new money.**

AI Summary

Revium Rx. (RVRC) filed an S-1/A on December 12, 2025, detailing a self-underwritten initial public offering (IPO) of up to 1,562,500 Units at a fixed price of $3.20 per Unit. Each Unit comprises two shares of common stock and one warrant to purchase one share of common stock at an exercise price of $2.40, exercisable for three years. Concurrently, the company is registering up to 37,625,790 shares for resale by existing selling stockholders, including 31,253,525 common shares and shares underlying 4,925,000 warrants at $0.80 and 1,447,265 warrants at $2.40. The resale offering will be at a fixed price of $1.00 per share until the stock is quoted on OTCQB or a national exchange. The company will not receive proceeds from the resale, except from cash exercise of Investor Warrants. The last reported sale price for RVRC common stock on the OTC Market was $0.52 per share on December 12, 2025, significantly below both the IPO Unit price and the resale price.

Why It Matters

This dual offering structure presents a significant challenge for Revium Rx.'s IPO, as the fixed resale price of $1.00 per share is substantially lower than the $3.20 per Unit IPO price, potentially deterring new investors. For existing investors, the ability to offload 37,625,790 shares at $1.00 could create substantial selling pressure, impacting the stock's market price. Competitors in the nano-medicine and antimicrobial resistance space will be watching to see if Revium Rx. can successfully navigate this complex capital raise, especially given the current OTC Market price of $0.52 per share, which suggests a disconnect with both offering prices.

Risk Assessment

Risk Level: high — The filing explicitly states, "The concurrent Resale Offering at a fixed price of $1.00 per share may adversely affect our ability to raise capital in the primary offering as the fixed resale price of $1.00 per share can be deemed by prospective investors as more attractive than the $3.20 price per unit in the primary offering." Furthermore, the last reported sale price on the OTC Market was $0.52 per share on December 12, 2025, indicating a significant valuation discrepancy and potential for immediate dilution for IPO investors.

Analyst Insight

Investors should exercise extreme caution and likely avoid the Revium Rx. IPO given the substantial pricing disparity between the primary offering ($3.20 per Unit) and the concurrent resale offering ($1.00 per share). The immediate availability of shares at a lower price from selling stockholders creates an unfavorable environment for new capital, suggesting a wait-and-see approach or outright avoidance until market dynamics stabilize and a clear valuation emerges.

Key Numbers

• 1,562,500 — Units offered in Primary Offering (Each Unit consists of two shares of common stock and one warrant)
• $3.20 — Price per Unit in Primary Offering (Fixed offering price for new investors)
• 37,625,790 — Shares offered in Resale Offering (Offered by Selling Stockholders)
• $1.00 — Price per share in Resale Offering (Fixed price for selling stockholders until OTCQB or national exchange listing)
• $0.52 — Last reported sale price on OTC Market (As of December 12, 2025, significantly below offering prices)
• $2.40 — Exercise price of IPO Warrants (Warrants included in the Primary Offering Units)
• 3 — Years (Expiration period for IPO Warrants)
• 365 — Days (Duration of the Primary Offering)

Key Players & Entities

• Revium Rx. (company) — Registrant for S-1/A filing
• RVRC (company) — Ticker symbol on OTCID
• Amir Avraham (person) — Principal Executive Officer
• David Aboudi, Esq. (person) — Legal counsel from Aboudi Legal Group PLLC
• Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• $3.20 (dollar_amount) — Fixed offering price per Unit in Primary Offering
• $1.00 (dollar_amount) — Fixed offering price per share in Resale Offering
• $0.52 (dollar_amount) — Last reported sale price for Common Stock on OTC Market on December 12, 2025
• OTC Markets Group, Inc. (company) — Operator of OTCID tier
• Nevada (company) — State of incorporation for Revium Rx.

FAQ

Risk Factors

• Self-Underwritten Offering and Limited Operating History [high — financial]: The company is conducting a self-underwritten IPO, meaning it is responsible for marketing and selling its own securities. This, combined with a limited operating history, presents significant risks. The offering price of $3.20 per Unit is substantially higher than the last reported OTC sale price of $0.52, indicating potential difficulty in achieving the offering's valuation.
• Significant Discount in Resale Offering Price [high — market]: The resale offering is priced at $1.00 per share, a steep discount to the primary offering's implied share price of $1.60 ($3.20 per Unit / 2 shares per Unit). This disparity suggests potential market concerns about the company's valuation or future prospects, as existing shareholders are willing to sell at a much lower price.
• Reliance on OTC Markets and Future Exchange Listing [medium — regulatory]: The company's common stock is currently quoted on the OTC Market, and the resale offering price is contingent on listing on OTCQB or a national exchange. Failure to achieve this listing could impact the resale price and overall marketability of the securities.
• Warrants with Low Exercise Prices [medium — financial]: The IPO Units include warrants exercisable at $2.40, and the resale registration includes warrants exercisable at $0.80 and $2.40. If the stock price does not significantly exceed these exercise prices, a large number of warrants could be exercised, potentially diluting existing shareholders and impacting the company's capital structure.
• Uncertainty in Future Performance and Projections [medium — operational]: The company acknowledges that projections and estimates of future performance are subject to uncertainty and risk. Factors described in the 'Risk Factors' section could cause actual results to differ materially from those expressed in forward-looking statements.

Industry Context

The pharmaceutical and biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Revium Rx. operate in a competitive landscape where innovation, intellectual property, and successful clinical trials are critical for market entry and success. The industry is also subject to evolving healthcare policies and reimbursement landscapes.

Regulatory Implications

As a pharmaceutical company, Revium Rx. is subject to stringent regulations from bodies like the FDA, governing drug development, testing, and marketing. Compliance with these regulations is costly and time-consuming, and any failure to adhere can result in significant penalties, delays, or denial of market approval.

What Investors Should Do

1. Analyze the significant price discrepancy between the primary offering ($3.20/Unit) and the resale offering ($1.00/share).
2. Evaluate the dilutive effect of the warrants included in the IPO Units and registered for resale.
3. Assess the company's ability to achieve its listing on OTCQB or a national exchange.
4. Scrutinize the company's limited operating history and self-underwritten offering structure.

Key Dates

• 2025-12-12: Filing of S-1/A for IPO — Details the terms of the initial public offering, including the number of units, price, and structure of the offering, as well as the registration of shares for resale.

Glossary

Self-underwritten IPO

An initial public offering where the issuing company manages the sale of its own securities directly to investors, rather than using an underwriter. (Indicates Revium Rx. is taking on the responsibility and risk of marketing and selling its shares, which can be challenging for companies with limited track records.)

Unit

A bundled security offered in an IPO, typically consisting of common stock and warrants. (In Revium Rx.'s IPO, each Unit includes two shares of common stock and one warrant, affecting the overall cost and potential return for investors.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) within a certain timeframe. (Warrants are included in Revium Rx.'s IPO Units and are also being registered for resale, impacting potential dilution and future capital raises.)

Resale Offering

An offering where existing shareholders sell their shares to the public, rather than the company issuing new shares. (A significant portion of the securities registered by Revium Rx. are for resale by existing stockholders, with a fixed price until exchange listing.)

OTC Market

Over-the-Counter market, a decentralized market where securities are traded directly between two parties without a central exchange. (Revium Rx.'s stock is currently trading on the OTC Market at a price significantly below the proposed IPO and resale offering prices.)

Year-Over-Year Comparison

As this is an S-1/A filing for an initial public offering, there is no prior comparable filing to assess year-over-year changes in key metrics like revenue, margins, or debt. The filing focuses on presenting the company's current structure, risks, and the terms of the proposed offering, rather than historical financial performance trends.

Key Financial Figures

• $0.001 — ists of (i) two shares of common stock, $0.001 par value per share (the “Common
• $2.40 — is exercisable at an exercise price of $2.40 per share, will be immediately exercisa
• $3.20 — offered at the fixed offering price of $3.20 per Unit. Notwithstanding our belief th
• $0.80 — olders at a per share exercise price of $0.80 and (iii) up to 1,447,265 shares issuab
• $1.00 — rospectus at a fixed price per share of $1.00. The concurrent Resale Offering at a fi
• $0.52 — our Common Stock on the OTC Market was $0.52 per share. The Selling Stockholders and

Filing Documents

• ea0268034-s1a3_revium.htm (S-1/A) — 1813KB
• ea026803401ex5-1_revium.htm (EX-5.1) — 12KB
• ea026803401ex10-18_revium.htm (EX-10.18) — 105KB
• ea026803401ex10-19_revium.htm (EX-10.19) — 8KB
• ea026803401ex23-1_revium.htm (EX-23.1) — 3KB
• image_001.jpg (GRAPHIC) — 36KB
• image_002.jpg (GRAPHIC) — 128KB
• image_003.jpg (GRAPHIC) — 20KB
• image_004.jpg (GRAPHIC) — 6KB
• image_005.jpg (GRAPHIC) — 8KB
• image_006.jpg (GRAPHIC) — 10KB
• image_007.jpg (GRAPHIC) — 28KB
• image_008.jpg (GRAPHIC) — 18KB
• image_009.jpg (GRAPHIC) — 5KB
• image_010.jpg (GRAPHIC) — 20KB
• image_011.jpg (GRAPHIC) — 15KB
• image_012.jpg (GRAPHIC) — 87KB
• image_013.jpg (GRAPHIC) — 13KB
• image_014.jpg (GRAPHIC) — 14KB
• image_015.jpg (GRAPHIC) — 25KB
• ex10-18_001.jpg (GRAPHIC) — 10KB
• ex23-1_001.jpg (GRAPHIC) — 2KB
• ex23-1_002.jpg (GRAPHIC) — 13KB
• 0001213900-25-121070.txt ( ) — 2574KB

Risk Factors

Risk Factors 5 Special Note About Forward-Looking Statements 30

Use of Proceeds

Use of Proceeds 31 Determination of the Offering Price 32 Capitalization 33

Dilution

Dilution 34 Market Price of and Dividends on the Company’s Common Equity 35 Management’s Discussion and Analysis of Financial Condition and Results of Operations of Revium Rx 36 Description of Business 46 Management 105

Executive Compensation

Executive Compensation 108

Security Ownership of Certain Beneficial Owners & Management

Security Ownership of Certain Beneficial Owners & Management 112 Certain Relationships and Related Transactions 113

Description of Securities

Description of Securities 114 Shares Eligible for Future Sale 116 Legal Matters 116 Experts 116 Where you Can Find More Information

Financial Statements of Revium Rx

Financial Statements of Revium Rx. F-1 i ABOUT THIS PROSPECTUS This Prospectus is part of a registration statement on Form S-1 that we filed with the U.S. Securities and Exchange Commission (the “SEC”). You should read this Prospectus and any documents that we incorporate by reference in this Prospectus before making an investment decision. You should rely only on the information contained in or incorporated by reference into this Prospectus. We have not authorized anyone to provide you with information different from that contained in this Prospectus or incorporated by reference herein. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this Prospectus. You must not rely on any unauthorized information or representation. This Prospectus is an offer by the Company to sell only the securities offered hereby but only under circumstances and in jurisdictions where it is lawful to do so. The distribution of this Prospectus and the issuance of the securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this Prospectus must inform themselves about, and observe any restrictions relating to, the issuance of the securities and the distribution of this prospectus outside the United States. This Prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, the securities offered by this Prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. Our business, financial condition, results of operations and prospects may have changed since those dates. Unless otherwise indicated, information contained in this Prospectus or incorporated by reference herein concerning our industry and the markets in which we operate is based on information from independent industry and research organizations, other

View Full Filing

View this S-1/A filing on SEC EDGAR